Literature DB >> 24589416

Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival.

David Ly1, Braden D Rowley2, Mark K Dodson3, Pat A Soisson3, Christopher J Jolles4, David K Gaffney5, William T Sause6.   

Abstract

OBJECTIVE: Unfavorable histology endometrial carcinomas confer worse prognosis. We determined the association of adjuvant radiation on local recurrence and survival for unfavorable, early stage endometrial cancer.
METHODS: We retrospectively identified 125 patients who had a hysterectomy for early stage (FIGO IA), unfavorable histology (clear cell, papillary serous or grade 3 endometrioid), endometrial carcinoma treated between 1992 and 2011. Patients were restaged according to current FIGO 2009 guidelines. Primary endpoint was local control and secondary endpoints were distant recurrence and overall survival.
RESULTS: The median age of the cohort was 67 years old with a mean follow up 152 months. Adjuvant radiation was delivered in 60 patients (48%). There were a total of 24 recurrences; 5 had local-regional recurrences, 4 local and distant recurrence, 12 distant only recurrences, and 3 had unspecified recurrences. The 5-year local-regional control was 97.8% in patients who received radiation and 80.1% in patients who did not receive radiation (p=0.018). The 5-year overall survival rate was 68.1% if patients did not receive radiation and 84.9% if they did receive radiation (p=0.0062). On univariate analysis, only radiation (HR 0.12, 95% CI: 0.03 to 0.49, p-value=0.018) was associated with a significant increase in local relapse free survival.
CONCLUSIONS: Adjuvant radiation therapy was significantly associated with an improvement in local-regional control and overall survival in patients with unfavorable histology, early stage endometrial cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell; Endometrial; Papillary serous; Radiation; Radiotherapy; Unfavorable histology

Mesh:

Year:  2014        PMID: 24589416     DOI: 10.1016/j.ygyno.2014.02.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma.

Authors:  Shari Damast; Susan A Higgins; Elena Ratner; Maria C De Leon; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Alessandro Santin; Thomas Rutherford; Peter E Schwartz
Journal:  J Contemp Brachytherapy       Date:  2015-01-26

Review 2.  Vaginal cuff brachytherapy in endometrial cancer - a technically easy treatment?

Authors:  Sebastià Sabater; Ignacio Andres; Veronica Lopez-Honrubia; Roberto Berenguer; Marimar Sevillano; Esther Jimenez-Jimenez; Angeles Rovirosa; Meritxell Arenas
Journal:  Cancer Manag Res       Date:  2017-08-09       Impact factor: 3.989

3.  Quantification of recurrence risk based on number of adverse prognostic factors in women with stage I uterine endometrioid carcinoma

Authors:  Andrew E Cook; Ibrahim Aref; Charlotte Burmeister; Miriana Hijaz; Mohamed A Elshaikh
Journal:  J Turk Ger Gynecol Assoc       Date:  2021-12-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.